Press
Release

2024

Vetbiolix Press Releases

Vetbiolix activates the option on the license for RQ-10 (VBX-3000), a 5-HT4 agonist discovered by RaQualia Pharma, to develop pet pharmaceuticals for the treatment of gut motility disorders in dogs and cats

Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its “First-in-class” drug candidates targeting osteoarthritis and canine and feline periodontitis

Vetbiolix communicates on the final results of the proof-of-concept study of VBX-2000 (piclidenoson) in canine osteoarthritis and on the upcoming submission of a regulatory pilot study vs. placebo

Vetbiolix communicates interim positive results from the proof-of-concept clinical study of its drug candidate VBX-2000 (piclidenoson; A3R agonist) in dogs suffering from osteoarthritis

VETBIOLIX announces Positive Results of the Proof-of-Concept Clinical Study of its drug-candidate VBX-1000 in periodontal disease in dogs

Vetbiolix strengthens its Top Management with the arrival of Dr Karine Bertrand as Chief Pharmaceutical & Technical Officer – Board Member